![肿瘤药物治疗方案及综合评价](https://wfqqreader-1252317822.image.myqcloud.com/cover/13/43604013/b_43604013.jpg)
上QQ阅读APP看本书,新人免费读10天
设备和账号都新为新人
晚期鼻咽癌化疗方案
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T41_223_1386_1974_1769_147332.jpg?sign=1738881479-RLmIUGAsuAyA10WyE2tCNV4DeZM9zbUm-0-ebe3b3f34b1051a3a3daad37b43b8d90)
方案评价
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T41_223_1853_1976_2809_147333.jpg?sign=1738881479-PnhQNU3OcIrdwPYjPMIH0vgB9YfWK33q-0-36238244bd23b59eeb38adfdb225795e)
续表
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T42_285_336_2020_1445_146913.jpg?sign=1738881479-aHr8IGoV6YL4FP4LBOM230igRQUHrCTB-0-81dbde4e109af3f9fed83fea83d9a233)
点评
本研究(NCT01528618)为Ⅲ期多中心随机对照试验,旨在比较晚期鼻咽癌中GP方案与传统PF方案的有效性和安全性,纳入中国22家医院总共362名ECOG PS评分0~1、器官功能良好、具有可测量病灶的复发或转移性鼻咽癌患者。结果发现:与PF方案相比,GP方案延长了患者生存期。该研究奠定了GP方案为晚期鼻咽癌一线姑息化疗首选方案的地位。
(彭星辰 谢钰鑫)
参考文献
[1] ZHANG L,HUANG Y,HONG S,et al.Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma:a multicentre,randomised,open-label,phase 3 trial.The Lancet,2016,388:1883-1892.